Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4042-4049

  Yamori, Takao ^a   Matsunaga, Akio ^b   Sato, Shigeo ^a   Yamazaki, Kanami ^a   Komi, Akiko ^a   Ishizu, Kazuhiro ^a   Mita, Izumi ^c   Edatsugi, Hajime ^c   Matsuba, Yasuhiro ^c   Takezawa, Kimiko ^c   Nakanishi, Osamu ^c   Kohno, Hiroshi ^b   Nakajima, Yuki ^b   Komatsu, Hironori ^b   Andoh, Toshio ^d   Tsuruo, Takashi ^e  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b MITSUI CHEMICALS INC   (Japan)

^c Mitsui Pharmaceuticals Inc   (Japan)

^d SOKA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[N [1 METHYL 2 [5 [N [4 [N,N (2 CHLOROETHYL)AMINO]PHENYL]]CARBAMOYL] 1H BENZIMIDAZOL 2 YL]PYRROL 4 YL]CARBAMOYL]ETHYLDIMETHYLSULFONIUM DI 4 TOLUENSULFONATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BLEOMYCIN DERIVATIVE; CARBOPLATIN; CARMOFUR; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEPLEOMYCIN; PIRARUBICIN; TEGAFUR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZIMIDAZOLES; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PYRROLES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033566690     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Turner, P. R., and Denny, W. A. The mutagenic properties of DNA minor-groove binding ligands. Mutat. Res., 355: 141-169, 1996.
2. Hartley, J. A., Lown, J. W., Mattes, W. B., and Kohn, K. W. DNA sequence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy. Acta. Oncol., 27: 503-510, 1988.
3. Lown, J. W. DNA recognition by lexitropsins, minor groove binding agents. J. Mol. Recognit. 7: 79-88, 1994.
4. Marchini, S., Cozzi, P., Beria, I., Geroni, C., Capolongo, L., D'Incalci, M., and Broggini, M. Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des., 13: 193-205, 1998.
5. Brooks, N., Lee, M., Wright, S. R., Woo, S., Centioni, S., and Hartley, J. A. Synthesis, DNA binding, cytotoxicity and sequence specificity of a series of imidazole-containing analogs of the benzoic acid mustard distamycin derivative tallimustine containing an alkylating group at the C-terminus. Anticancer Drug Des., 12: 591-606, 1997.
6. Yoon, J. H., and Lee, C. S. Sequence selectivity of DNA alkylation by adozelesin and carzelesin. Arch. Pharmacal Res. (Seoul), 21: 385-390, 1998.
7. Bhuyan, B. K., Smith, K. S., Adams, E. G., Wallace, T. L., Von Hoff, D. D., and Li, L. H. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects. Cancer Chemother. Pharmacol., 30: 348-354, 1992.
8. Burris, H. A., Dieras, V. C., Tunca, M., Earhart, R. H., Eckardt, J. R., Rodriguez, G. I., Shaffer, D. S., Fields, S. M., Campbell, E., Schaaf, L., Kasunic, D., and Von Hoff, D. D. Phase I study with the DNA sequence-specific agent adozelesin. Anticancer Drugs, 8: 588-596, 1997.
9. Foster, B. J., LoRusso, P. M., Poplin, E., Zalupski, M., Valdivieso, M., Wozniak, A., Flaherty, L., Kasunic, D. A., Earhart, R. H., and Baker, L. H. Phase I trial of adozelesin using the treatment schedule of daily ×5 every 3 weeks. Invest. New Drugs, 13: 321-326, 1996.
10. Li, L. H., DeKoning, T. F., Kelly, R. C., Krueger, W. C., McGovren, J. P., Padbury, G. E., Petzold, G. L., Wallace, T. L., Ouding, R. J., Prairie, M. D., and Gebhard, I. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res., 52: 4904-4913, 1992.
11. Houghton, P. J., Cheshire, P. J., Hallman, J. D. N., and Houghton, J. A. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 36: 45-52, 1995.
12. Carter, C. A., Waud, W. R., Li, L. H., DeKoning, T. F., McGovren, J. P., and Plowman, J. Preclinical antitumor activity of bizelesin in mice. Clin. Cancer Res., 2: 1143-1149, 1996.
13. Walker, D. L., Reid, J. M., and Ames, M. M. Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother. Pharmacol., 34: 317-322, 1994.
14. Kobayashi, E., Okamoto, A., Asada, M., Okabe, M., Nagamura, S., Asai, A., Saito, H., Gomi, K., and Hirata, T. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res., 54: 2404-2410, 1994.
15. Pezzoni, G., Grandi, M., Biasoli, G., Capolongo, L., Ballinari, D., Giuliani, F. C., Barbieri, B., Pastori, A., Pesenti, E., Mongelli, N., and Spreafico, F. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A. Br. J. Cancer, 64: 1047-1050, 1991.
16. Verweij, J. New promising anticancer agents in development: what comes next? Cancer Chemother. Pharmacol., 38 (Suppl.): S3-S10, 1996.
17. Viallet, J., Stewart, D., Shepherd, F., Ayoub, J., Cormier, Y., DiPietro, N., and Steward, W. Tallimustine is inactive in patients with previously treated small cell lung cancer. A Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Lung Cancer, 15: 367-373, 1996.
18. Punt, C. J., Humblet, Y., Roca, E., Dirix, L. Y., Wainstein, R., Polli, A., and Corradino, I. Tallimustine in advanced previously untreated colorectal cancer, a Phase II study. Br. J. Cancer, 73: 803-804, 1996.
19. Alberts, S. R., Erlichman, C., Reid, J. M., Sloan, J. A., Ames, M. M., Richardson, R. L., and Goldberg, R. M. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Cancer Res., 4: 2111-2117, 1998.
20. Tabernero, L., Verdaguer, N., Coll, M., Fita, I., van der Marel, G. A., van Boom, J. H., Rich, A., and Aymami, J. Molecular structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor groove binding drug netropsin. Biochemistry, 32: 8403-8410, 1993.
21. Stinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H. H., Mullendore, L. A., Pittman, A. F., Kenney, S., Keller, J., and Boyd, M. R. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res., 12: 1035-1053, 1992.
22. Satoh, A., Takayama, E., Kojima, K., Ogawa, H., Yamori, T., Sato, S., Kawaguchi, T., Tsuruo, T., Yoshimoto, K., Kine, T., and Matsumoto, I. Expression of carbohydrate-binding protein p33/41 human tumor cell lines. J. Biochem., 119: 346-353, 1996.
23. Motoyama, T., Hojo, H., and Watanabe, H. Comparison of seven cell lines derived from human gastric carcinomas. Acta. Pathol. Jpn., 36: 65-83, 1986.
24. Boyd, M. R. Status of the National Cancer Institute preclinical antitumor drug discovery screen: implications for selection of new agents for clinical trial. In: V. T. Devita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology Update, Vol. 3, pp. 1-12. Philadelphia: Lippincott, 1989.
25. Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 81: 1088-1092, 1989.
26. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrichi, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-766, 1991.
27. Yamori, T., Sato, S., Chikazawa, H., and Kadota, T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn. J. Cancer Res., 88: 1205-1210, 1997.
28. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
29. Goldwasser, F., Shimizu, T., Jackman, J., Hoki, Y., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56: 4430-4437, 1996.
30. Ishizawa, M., Kobayashi, Y., Miyamura, T., and Matsuura, S. Simple procedure of DNA isolation from human serum. Nucleic Acids Res., 19: 5792, 1991.
31. 6-ethyl-G-C base pairs stabilized by minor groove binding drugs: molecular structure of d(CGC[e6G]AATTCGCG complexed with Hoechst 33258 or Hoechst 33342. EMBO J., 11: 225-232, 1992.
32. Robinson, H., Gao, Y. G., Bauer, C., Roberts, C., Switzer, C., and Wang, A. H. 2′-Deoxyisoguanosine adopts more than one tautomer to form base pairs with thymidine observed by high-resolution crystal structure analysis. Biochemistry, 37: 10897-10905, 1998.
33. Chen, A. Y., Yu, C., Gatto, B., and Liu, L. F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA, 90: 8131-8135, 1993.
34. Montecucco, A., Fontana, M., Focher, F., Lestingi, M., Spadari, S., and Ciarrocchi, G. Specific inhibition of human DNA ligase adenylation by a distamycin derivative possessing antitumor activity. Nucleic Acids Res., 19: 1067-1072, 1991.
35. Wang, Z., Zimmer, C., Lown, J. W., and Knippers, R. Effects of bifunctional netropsin-related minor groove-binding ligands on mammalian type I DNA topoisomerase. Biochem. Pharmacol., 53: 309-316, 1997.
36. Fesen, M., and Pommier, Y. Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA. J. Biol. Chem., 264: 11354-11359, 1989.
37. Bellorini, M., Moncollin, V., D'Incalci, M., Mongelli, N., and Mantovani, R. Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res., 23: 1657-1663, 1995.
38. Broggini, M., and D'Incalci, M. Modulation of transcription factor-DNA interactions by anticancer drugs. Anticancer Drug Des., 9: 373-387, 1994.
39. Erba, E., Mascellani, E., Pifferi, A., and D'Incalci, M. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int. J. Cancer, 62: 170-175, 1995.
40. Zhang, X., and Kiechle, F. L. Hoechst 33342 induces apoptosis and alters TATA box binding protein/DNA complexes in nuclei from BC3H-1 myocytes. Biochem. Biophys. Res. Commun., 248: 18-21, 1998.
41. Zhang, X., and Kiechle, F. L. Mechanism of Hoechst 33342-induced apoptosis in BC3H-1 myocytes. Ann. Clin. Lab. Sci., 28: 104-114, 1998.
42. Kamesaki, H. Mechanisms involved in chemotherapy-induced apoptosis and their implications in cancer chemotherapy. Int. J. Hematol., 68: 29-43, 1998.